Guideline for the Diagnosis and Management of Atrial Fibrillation
The most common sustained arrhythmia, atrial fibrillation (AF), is the focus of a 2023 guideline from the American College of Cardiology (ACC) and American Heart
The most common sustained arrhythmia, atrial fibrillation (AF), is the focus of a 2023 guideline from the American College of Cardiology (ACC) and American Heart
In Taiwan, the use of non–vitamin K antagonist oral anticoagulants (NOACs) before alteplase-treated acute ischemic stroke did not increase the risk of intracranial hemorrhage, major
An understudied group that is at risk for venous thromboembolism (VTE), patients aged 90 years or older had outcomes with anticoagulation different from those in
In a post hoc analysis of the HOST-EXAM (Harmonizing Optimal Strategy for Treatment of coronary artery diseases—EXtended Antiplatelet Monotherapy) trial, clopidogrel had consistently better outcomes
In the Pre-hospital Antifibrinolytics for Traumatic Coagulopathy and Hemorrhage (PATCH-Trauma) trial, functional outcomes at 6 months in adults with major trauma and suspected trauma-induced coagulopathy
Dual antiplatelet therapy (DAPT) was noninferior to intravenous thrombolysis with alteplase in a trial of patients with minor nondisabling acute ischemic stroke presenting within 4.5
Among 32,715 patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke, recent use of vitamin K antagonists (VKAs) was not associated with significantly increased risk
In a study prematurely terminated for recruitment difficulties and a low event rate, rivaroxaban did not reduce a composite endpoint of venous and arterial thrombotic
A randomized trial of 334 patients with severe hypoxemic COVID-19 pneumonia supports the empirical use of high-dose prophylactic anticoagulation (HD-PA). “The results of the ANTICOVID
An exploratory analysis of a multiplatform adaptive randomized controlled trial (RCT) demonstrates heterogeneity of responses to therapeutic-dose heparin in patients hospitalized for COVID-19. In all 3